Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coagulation01:09

Coagulation

8.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
8.4K
Coagulation01:06

Coagulation

491
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
491
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.1K
Disorders of Hemostasis01:24

Disorders of Hemostasis

1.4K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.4K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.5K
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

12.0K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
12.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Growth differentiation factor-15 and bleeding risk in patients with venous thromboembolism.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Clonal hematopoiesis and thrombosis risk-what are research and clinical gaps?

Research and practice in thrombosis and haemostasis·2026
Same author

Risk Factors, Biomarkers, and Risk Assessment Models for Prediction of Venous Thromboembolism in Ambulatory Patients with Advanced Lung Cancer.

Hamostaseologie·2026
Same author

Subjective theory of illness, disease perception, and attitude toward anticoagulation therapy in patients with unprovoked venous thromboembolism-the qualitative Dalí study.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Comparison of People with Hemophilia A and Patients with Nonvalvular Atrial Fibrillation on Oral Anticoagulation by Thrombin Generation.

Thrombosis and haemostasis·2026
Same author

The road to Paris: ISTH 2026 Congress sets to debut the latest science and innovation.

Journal of thrombosis and haemostasis : JTH·2026

Related Experiment Video

Updated: Oct 25, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

933

[Title: Covid-19-associated coagulopathy].

Stephan Nopp1, Cihan Ay1

  • 1Klinische Abteilung für Hämatologie und Hämostaseologie, Universitätsklinik für Innere Medizin I, Medizinische Universität Wien, Österreich.

Deutsche Medizinische Wochenschrift (1946)
|August 3, 2021
PubMed
Summary

COVID-19 causes blood clots (thromboembolism) due to coagulopathy. Anticoagulation is recommended for hospitalized patients, but optimal dosage remains under investigation.

More Related Videos

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

775
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.1K

Related Experiment Videos

Last Updated: Oct 25, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

933
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

775
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.1K

Area of Science:

  • Medicine
  • Infectious Diseases
  • Hematology

Background:

  • COVID-19, initially viewed as a respiratory illness, is now recognized as a multi-systemic disease.
  • Severe COVID-19 cases exhibit significant blood coagulation abnormalities, increasing risks of venous and arterial thromboembolism.
  • This prothrombotic state, termed COVID-19-associated coagulopathy (CAC), involves infectious agents, inflammation, and the coagulation system.

Purpose of the Study:

  • To provide an overview of the current understanding of COVID-19-associated coagulopathy.
  • To discuss the clinical and therapeutic implications of CAC.

Main Methods:

  • Review of current scientific literature on COVID-19 and coagulopathy.
  • Analysis of key hematological markers associated with severe COVID-19.
  • Discussion of existing treatment guidelines and ongoing debates regarding anticoagulation strategies.

Main Results:

  • COVID-19-associated coagulopathy is characterized by elevated D-dimer, high fibrinogen, prolonged prothrombin time, and thrombocytopenia.
  • The prothrombotic nature of CAC necessitates prophylactic anticoagulation in hospitalized patients.
  • Optimal anticoagulation dosage in COVID-19 patients is a subject of ongoing clinical debate.

Conclusions:

  • COVID-19-associated coagulopathy presents a significant thrombotic risk, requiring careful management.
  • Prophylactic anticoagulation is a standard recommendation for hospitalized COVID-19 patients.
  • Further research is needed to determine the optimal anticoagulation dosage for managing CAC.